Mapi-Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mapi-pharma.com
Clinical Trials
6
Active:3
Completed:2
Trial Phases
4 Phases
Phase 1:3
Phase 2:1
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Not Applicable
1 (16.7%)Phase 2
1 (16.7%)Phase 3
1 (16.7%)Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
Not Applicable
Recruiting
- Conditions
- Major Depressive Disorder (MDD)Bipolar 1 DisorderSchizophrenia
- Interventions
- Drug: Cariprazine DepotDrug: Cariprazine Depot MTDDrug: Oral Cariprazine 3 mg/day
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT07185815
- Locations
- 🇮🇱
Tel Aviv, Israel, Tel Aviv, Israel
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Other: Placebo
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 1016
- Registration Number
- NCT04121221
- Locations
- 🇺🇦
Mapi Pharma Research site 08, Kherson, Ukraine
🇺🇦Mapi Pharma Research site 11, Chernivtsi, Ukraine
🇷🇺Mapi Pharma Research site 15, Smolensk, Russian Federation
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Phase 2
Active, not recruiting
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- Drug: GA Depot 40mg once monthlyDrug: GA Depot 25mg once monthly
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03362294
- Locations
- 🇮🇱
Mapi Pharma Research site 09, Haifa, Israel
🇮🇱Mapi Pharma Research site 07, Jerusalem, Israel
🇮🇱Mapi Pharma Research site 08, Petah tikva, Israel
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: GA Depot 40 mgDrug: GA Depot 80 mg
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02212886
- Locations
- 🇮🇱
Barzilai Medical Center, Ashkelon, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
🇮🇱TASMC, Tel Aviv, Israel
News
No news found